Santhera Pharmaceuticals
Pratteln, Basel-Landschaft, Switzerland · Biopharma, Biotechnology, Health Care
Santhera Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of rare neuromuscular and pulmonary diseases.
Key facts
- Headquarters
- Pratteln, Basel-Landschaft, Switzerland
- Employees
- 78
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- santhera.com
- Company page
Recent activity at Santhera Pharmaceuticals
- : Santhera Pharmaceuticals Appoints Marc Clausse as Chief Commercial Officer
- : Santhera Pharmaceuticals Forms Exclusive Agreement with Biomedica for AGAMREE® Distribution in Russia.
- : Santhera Pharmaceuticals raises CHF 20 million in growth funding led by R-Bridge and Highbridge Capital Management to accelerate global AGAMREE rollout.
- : Santhera Pharmaceuticals Appoints Catherine Isted as CFO, Andrew Smith to Step Down
- : Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
Santhera Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Funding Round | $20.0M |
Leadership
- Marc Clausse, Chief Commercial Officer
- Geert Jan van Daal, Chief Commercial Officer
- Catherine Isted, Chief Financial Officer
- Geert Jan van Daal, Chief Commercial Officer
- Marc Schrader, Chief Technology Officer
Verified email and direct lines for Santhera Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Santhera Pharmaceuticals in the news
- Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea - Yahoo Finance UK (Oct 23, 2026)
- Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026 - Yahoo Finance UK (Sep 30, 2026)
- Santhera Expands Biomedica Agreement to Extend AGAMREE® - GlobeNewswire (Jul 13, 2026)
- Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025 - Yahoo Finance UK (Apr 28, 2026)
- Santhera preps UK Duchenne drug launch after NICE says yes - pharmaphorum (Jan 16, 2025)
- Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE® - GlobeNewswire (Jul 01, 2026)
- Destiny calls time on SporeGen COVID collab, while Santhera hands lonodelestat back to Spexis - Fierce Biotech (Apr 25, 2024)
- Santhera Appoints Orlando Oliveira as Chief Executive Officer - Yahoo! Finance Canada (Apr 23, 2026)
Companies similar to Santhera Pharmaceuticals
- Minerva Neurosciences · Biopharma, Biotechnology, Health Care, Pharmaceutical, pharmaceuticals, Therapeutics
- Pfizer · Biopharma, Biotechnology, Health Care, Pharmaceutical, pharmaceuticals, Therapeutics
- Centessa Pharmaceuticals plc · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Timberlyne Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Abivax · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Santhera Pharmaceuticals: questions and answers
What does Santhera Pharmaceuticals do?
Santhera Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of rare neuromuscular and pulmonary diseases.
Where is Santhera Pharmaceuticals headquartered?
Santhera Pharmaceuticals is headquartered in Pratteln, Basel-Landschaft, Switzerland.
How many employees does Santhera Pharmaceuticals have?
Santhera Pharmaceuticals has about 78 employees.
Has Santhera Pharmaceuticals raised funding?
Yes. Fundz has recorded 1 funding event for Santhera Pharmaceuticals. The most recent, Funding Round of $20.0M, was in Sep 2025.
What is the latest news on Santhera Pharmaceuticals?
On Mar 10, 2026, Santhera Pharmaceuticals Appoints Marc Clausse as Chief Commercial Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy